Johnson & Johnson reported $33.8 billion in MedTech sales for 2025, a 6.1% increase from the prior year.
Operational sales for the segment grew 5.4%, driven by cardiovascular and surgical products, according to a Jan. 21 earnings release. The company also highlighted regulatory progress on its robotic surgical system, which was submitted for review in 2025. The platform is part of J&J’s broader strategy to expand its footprint in minimally invasive and digitally integrated surgery.
J&J projects reported sales of up to $101 billion in 2026, with MedTech performance expected to remain a key driver.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
